Loading…
← CockpitCompetitor Analysis › 085660.KS CHA Biotech Co., Ltd.Open in the cockpit ↗

CHA Biotech Co., Ltd.085660.KSCompetitor analysis, valuation and peers

South Korea · KRW·Information Technology›Electronic Components
Momentum weak 30
Mkt cap
$499M
US dollars, full cap
Free float
75%
of shares outstanding
$/day
$1.26M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-8.5 pp
WACC 5.5%
Hurdle
n/a
no reverse DCF
Close · KRW₩7,290
1D0.0%
1W+8.0%
1M-14.8%
3M-23.3%
6M-57.3%
YTD-50.3%
1Y-44.9%
ATR %5.4%
52w lowhigh69.6% off high

What CHA Biotech does

Employees: 354

CHA Biotech at a glance

Size CHA Biotech (085660.KS) is a South Korea Information Technology company (Electronic Components) with a market value of $499M, the 333rd largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩7,290 on 6 Nov 2026.

Performance Over six months the shares fell 57.3%, against -27.3% for the median peer and -24.5% for the South Korea market (cap-weighted) — 3rd lowest of 21 in its peer set.

Growth Revenue grew 13.9% over the last twelve months (peer median +19.1%); the operating margin is -5.7% (peer median 3.2%).

Valuation It trades at 1.3× enterprise value to sales against a peer median of 3.7× (3rd cheapest of 21).

Capital Return on invested capital runs 8.5 points below its cost of capital (5.5% WACC).

Relative performance

507510011 May 202611 Aug 20266 Nov 2026Peer median 72085660.KS 43
Six months, rebased to 100: CHA Biotech against the median of its 20 peers (local-currency closes).

CHA Biotech financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩1.31T₩1.27T₩1.05T₩954B₩845B
Revenue growth—+21%+10%+13%—
Gross profit₩331B₩324B₩247B₩255B₩189B
EBITDA-₩17.4B-₩854M-₩15.0B₩28.4B-₩20.9B
Net income₩14.3B-₩110B-₩4.76B-₩8.43B-₩47.5B
Free cash flow-₩283B-₩219B-₩142B-₩62.9B-₩142B
Capital expenditure₩187B₩152B₩98.5B₩74.4B₩129B
Total debt₩816B₩831B₩759B₩450B₩401B

Quarterly statements and history in the cockpit →

CHA Biotech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%LPTH33626880106782605258SMOP80423568605439SENS231668829130151700244941720023550653503010414207703526085660.KS6-month return →1-month return →
Up and to the right = strong over both horizons. CHA Biotech is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%+100%2.5×5×7.5×10×LPTH33626880106782605258SMOP80423568605439SENS23166882913015170024492355065350301041420770085660.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. CHA Biotech is the large dot.

CHA Biotech competitors and peer comparison

How CHA Biotech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

CHA Biotech against its 20 peers (data as of 6 Nov 2026)
Measure085660.KSPeer medianRank in peer set
1-month return-14.8%-18.5%9th highest of 21
6-month return-57.3%-27.3%3rd lowest of 21
Distance from 52-week high-69.6%-50.4%3rd lowest of 21
Revenue growth (TTM)+13.9%+19.1%9th lowest of 21
Operating margin-5.7%3.2%7th lowest of 21
EV / Sales1.3×3.7×3rd cheapest of 21
ROIC minus cost of capital-8.5 pp-2.4 pp8th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
CHA Biotech 085660.KSSouth Korea$499M-57%+14%-6%1.3×n/an/a
LightPath Technologies LPTHUnited States$495M-39%+93%-2%5.9×n/an/a
Ability Opto-Electronics Technology 3362.TWOTaiwan$513M+6%-3%-8%5.1×n/an/a
Fujian Forecam Optics 688010.SSChina$518M-35%-2%-15%5.8×n/an/a
Visco Vision 6782.TWTaiwan$523M+23%+23%29%3.6×n/an/a
Jiangsu Xiehe Electronic 605258.SSChina$476M-2%+1%7%3.1×8.6%+9.7%
Smartoptics SMOP.OLNorway$530M-8%+45%14%4.7×15.2%+19.1%
Taiwan Chinsan Electronic Industrial 8042.TWOTaiwan$541M+82%+22%7%4.5×n/an/a
TLB 356860.KSSouth Korea$460M-34%+43%13%2.0×n/an/a
First Hi-tec Enterprise 5439.TWOTaiwan$458M-60%+93%17%1.4×-5.0%+31.1%
Senseonics SENSUnited States$454M+71%+91%-223%7.7×n/an/a
WUS Printed Circuit 2316.TWTaiwan$549M-15%+24%-11%3.8×n/an/a
Beijing JCZ Technology 688291.SSChina$452M-30%+12%1%9.7×n/an/a
Shaanxi Huada Science Technology 301517.SZChina$554M-54%-9%-26%6.9×n/an/a
Foshan Nationstar Optoelectronics 002449.SZChina$557M-24%-17%-6%1.4×n/an/a
LS Materials 417200.KSSouth Korea$442M-70%+20%0%3.6×n/an/a
Chin-Poon Industrial 2355.TWTaiwan$568M-9%+1%4%0.8×7.2%+0.6%
Shinsung Delta Tech 065350.KSSouth Korea$572M-51%+10%3%1.2×n/an/a
Shenzhen King Brother Electronics Technology 301041.SZChina$430M-10%+18%5%3.1×22.5%+3.9%
GigaVis 420770.KSSouth Korea$583M-40%+176%26%10.1×34.7%-5.1%
Alltop Technology 3526.TWOTaiwan$428M-40%+19%31%2.8×-7.5%+12.9%

Questions

Which companies are CHA Biotech's closest peers?
The cockpit's peer set: LightPath Technologies (LPTH), Ability Opto-Electronics Technology (3362.TWO), Fujian Forecam Optics (688010.SS), Visco Vision (6782.TW), Jiangsu Xiehe Electronic (605258.SS), Smartoptics (SMOP.OL), Taiwan Chinsan Electronic Industrial (8042.TWO), TLB (356860.KS).
Is CHA Biotech expensive compared with its peers?
On ev / sales it trades at 1.3× against a peer median of 3.7×, 3rd cheapest of 21 in its peer set.
How has CHA Biotech stock performed?
Over six months to 6 Nov 2026 the shares returned -57.3% against -27.3% for the median peer; over one year -44.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.